Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
2004-12-24
2011-12-06
Wilson, Michael C. (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C800S003000, C800S021000, C435S325000
Reexamination Certificate
active
08071839
ABSTRACT:
The present invention relates to transgenic non-human mammals comprising a polynucleotide encoding a human or humanized C5aR. The invention also relates to use of the transgenic non-human mammals in methods of screening for agonists, inverse agonists and antagonists of human C5aR and for testing efficacy of C5aR agonists, inverse agonists and antagonists in various animal models of disease.
REFERENCES:
patent: WO9833908 (1994-08-01), None
patent: WO 94/20142 (1994-09-01), None
patent: WO 95/00164 (1995-01-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO9833908 (1998-08-01), None
patent: WO 02/061087 (2002-08-01), None
patent: WO 02059263 (2002-08-01), None
patent: WO 03027252 (2003-04-01), None
patent: WO2004040000 (2004-05-01), None
Lee (Nature Biotech., Oct. 2006, vol. 24, No. 10, p. 1279-1284).
Monk (British J. Pharm., 2007, vol. 152, p. 429-448).
Sato (Thrombosis and Haemostasis, 1999, vol. 82, No. 2, p. 865-869).
Roebroek (Methods in Molecular Biology, 2003, vol. 209, 187-200).
Homanics (2002, Methods in Alcohol related neuroscience research, Editor, Liu, Yuan, p. 31-61).
Lester (Current Opin. Drug Discovery and Development, 2003, vol. 6, No. 5, p. 633-639).
Champtiaux (Current Drug Targets—CNS & Neurological Disorders, 2002, vol. 1, p. 319-330.
Girardi (J. Clin. Invest., Dec. 2003, vol. 112, No. 11, p. 1644-1654).
Wong (IDrugs, 1999, vol. 2, p. 686-693).
Cain (Biochemical Pharm., 2001, vol. 61, No. 12, p. 1571-1579).
Woodruff (Inflammation, 2001, vol. 25, No. 3, p. 171-177).
Drago (Cellular and molecular life sciences, Jul. 2003, vol. 60, p. 1267-1280).
Gu (Developmental Cell, Jul. 2003, vol. 5, p. 45-57).
Woodruff (Arthritis and Rheumatism, Sep. 2002, vol. 46, No. 9, p. 2476-2485).
Kedmi, Society for Neurosci. Abstract Viewer and Itinerary Planner, 2003, vol. 2003, pp Abstract No. 533.12.
Wang, Blood, 2002, vol. 11, Nol. 11, Abstract 2681.
Rozmahel (Human Mol. Genetics, 1997, vol. 6, Nol. 7, p. 1153-1162).
Gerard, N. P. et al. Human chemotaxis receptor genes cluster at 19q13.3-13.4. characterization of the human C5a receptor gene. Biochemistry (1993), 32: 1243-1250.
Höpken, U.E. et al. The C5a chemoattractant receptor mediates mucosal defence to infection, Nature (1996), 383: 86-89.
Heller et al. Selection of a C5a receptor antagonist from phage libraries attenuating the inflammatory response in immune complex disease and ischemia/reperfusion injury. The Journal of Immunology (1999) 163: 985-994.
Köhl, J. et al. Anaphylatoxins and infectious and non-infectious inflammatory diseases. Molecular Immunology (2001) 38: 175-187.
Berman et al. “Lymphocyte motility and lymphocyte chemoattractant factors.” Immunol. Invest. (1988), 17: 625-677.
Kavanaugh et al. “Role of CD11/CD18 in adhesion and transendothelial migration of T cells,” J. Immunol., (1991) 146: 4149-4156.
Prosser, et al., Targeted replacement of rodent CCR2 with the human orthologue CCR2B: A mouse model for in vivo analysis of human target-selective small molecule MCP-1 receptor antagonists, Drug Development Research, vol. 55 Issue 4, pp. 197-209, Published Online: Jun. 21, 2002.
Hugli et al., The active site of human C4a anaphylatoxin. Mol. Immunol. 1983;20:637-45.
Lienenklaus et al., Human anaphylatoxin C4a is a potent agonist of the guinea pig but not the human C3a receptor. J. Immunol. 1998;161:2089-93.
Mukherjee et al., The role of complement anaphylatoxin C5a in neurodegradation: Implications in Alzheimer's Disease. J. Neuroimmun. 2000;105(2)124-30.
Muller, Ten years of gene targeting: targeted mouse mutants, from vector design to phenotype analysis. Mech. Dev. 1999;82:3-21.
Woodruff et al., Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Inflammation 2001;25:171-7.
Dymecki, Susan M., Flp recombinase promotes site-specific DNA recombination in embryonic stem cells and transgenic mice., Proc Natl Acad Sci U S A. Jun. 11, 1996;93(12):6191-6196.
Takeuchi,et al., Flp recombinase transgenic mice of C57BL/6 strain for conditional gene targeting., Biochem Biophys Res Commun. May 10, 2002;293(3):953-957.
Layton et al., “Cross-species Receptor Binding Characteristics of Human and Mouse Leukemia Inhibitory Factor Suggest a Complex Binding Interaction,” J Biol. Chem., 1994, 269(25), 17048-17055.
Mosmann et al., “Species-specificity of T cell stimulating activities of IL 2 and BSF-1 (IL 4): comparison of normal and recombinant, mouse and human IL 2 and BSF-1 (IL 4),” J. Immunol., 1987, 138, 1813-1816.
Liu et al., “The α chain of the IL-2 receptor determines the species specificity of high-affinity IL-2 binding,” Cytokine, 1996, 8(8), 613-621.
Höpken et al., “The C5a chemoattractant receptor mediates mucosal defence to infection,” Letters to Nature, 1996, 383, 86-89.
Labarca et al., “Point mutant mice with hypersensitive α4 nicotinic receptors show dopaminergic deficits and increased anxiety,” PNAS, 2001, 98(5), 2786-2791.
Smith et al., “Species Specificity of Human and Murine Tumor Necrosos factor,” J. Biol. Chem., 1986, 261(32), 14871-14874.
Bozicevic Field & Francis LLP
Francis Carol L.
G2 Inflammation Pty Ltd
Wilson Michael C.
LandOfFree
Transgenic mouse comprising a polynucleotide encoding human... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic mouse comprising a polynucleotide encoding human..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic mouse comprising a polynucleotide encoding human... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4262572